1. 152OEfficacy and safety of the Met inhibitor tepotinib in patients (pts) with advanced Met+ hepatocellular carcinoma (HCC) previously treated with sorafenib. (25th November 2018) Authors: Decaens, T; Barone, C; Assenat, E; Wermke, M; Fasolo, A; Merle, P; Blanc, J-F; Grando, V; Bruns, R; Straub, J; Zhao, C; Faivre, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 67PPooled safety analysis of tepotinib in Asian patients with advanced solid tumours. (24th November 2019) Authors: Yamazaki, K; Ryoo, B-Y; Doi, T; Paik, P K; Veillon, R; Decaens, T; Faivre, S; Falchook, G S; Hong, D S; Scheele, J; Bruns, R; Berghoff, K; Qin, S Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 698PPhase II efficacy and safety data for the MET inhibitor tepotinib in patients (pts) with sorafenib-treated advanced hepatocellular carcinoma (HCC). (23rd October 2018) Authors: Decaens, T; Barone, C; Assenat, E; Wermke, M; Fasolo, A; Merle, P; Blanc, J F; Grando, V; Bruns, R; Straub, J; Zhao, C; Faivre, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 783TiPCA209-9DX: phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation. (23rd October 2018) Authors: Jimenez Exposito, M J; Akce, M; Montero Alvarez, J L; Assenat, E; Balart, L A; Baron, A D; Decaens, T; Heurgue-Berlot, A; Martin, A O; Paik, S W; Poulart, V; Sehbai, A S; Takemura, N; Yoon, J-H Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗